• Explore /
  • Poster
  • / Lorlatinib for advanced ALK and ROS1+ non-small cell lung cancer (NSCLC): Efficacy and treatment sequences in the IFCT-1803 LORLATU expanded access program (EAP) cohort.

Lorlatinib for advanced ALK and ROS1+ non-small cell lung cancer (NSCLC): Efficacy and treatment sequences in the IFCT-1803 LORLATU expanded access program (EAP) cohort.

Abstract Video & Slides Poster

Authors

null

Simon Baldacci

Thoracic Oncology Department, Lille University Hospital, Lille, France

Simon Baldacci , Virginie Avrillon , Benjamin Besse , Bertrand Mennecier , Michael Duruisseaux , Julien Mazieres , Renaud Descourt , Helene Doubre , Pascale Dubray-Longeras , Jacques Cadranel , Denis Moro-Sibilot , Charles Ricordel , Sigolène Galland-Girodet , Isabelle Monnet , Josiane Otto , Sophie Schneider , Pascale Missy , Franck Morin , Virginie Westeel , Nicolas Girard

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Citation

J Clin Oncol 38: 2020 (suppl; abstr 9615)

DOI

10.1200/JCO.2020.38.15_suppl.9615

Abstract #

9615

Poster Bd #

381

Abstract Disclosures

Similar Posters

First Author: Hongyun Zhao

Poster

2020 ASCO Virtual Scientific Program

Resistance to lorlatinib in <em>ROS1</em> fusion-positive non-small cell lung cancer.

Resistance to lorlatinib in ROS1 fusion-positive non-small cell lung cancer.

First Author: Jessica Jiyeong Lin

First Author: Benjamin Besse

First Author: Todd Michael Bauer